Varfarin ile Oluşan İlaç ve Besin Etkileşimleri

Year 2021, Volume: 2 Issue: 1, 43 - 47, 06.03.2021

Sinem Gürcü , Ebru Avcı Özlem Kutsal

https://doi.org/10.48176/esmj.2021.16

Abstract

Tromboembolizm tedavisinde sıklıkla kullanılan varfarin, güçlü bir antikoagülandır. Dar terapötik indeksli bir ilaçtır ve terapötik doz aşıldığında kanama riski oluşmaktadır. Birçok ilaç ve besin ile etkileşimi söz konusudur. İlaç ve besin etkileşimleri sebebi ile tedavi etkinliği azalmakta veya spontan kanamalar meydana gelmektedir. İlaç etkileşimleri advers ilaç reaksiyonlarının küçük bir kısmını oluşturmasına rağmen, öngörülebilir ve önlenebilir mortalite ve morbidite sebebi olması nedeni ile önemlidir. İlaç etkileşimlerinin önlenmesi hastanede kalış süresinin kısalmasını, yeniden başvuru oranının azalmasını ve tedavi maliyetlerinin azalmasını sağlar. Hastalara uygulanan tedavinin ilaç etkileşimleri açısından incelenmesi, tedavi etkinliğini ve güvenilirliğini artırmaktadır. Bu derlemenin amacı, varfarinin ilaç ve besin etkileşimleri hakkında bilgi düzeyinin artırılmasıdır.

Keywords

Varfarin, ilaç etkileşimleri, besin-ilaç etkileşimleri

Drug and Food Interactions with Warfarin

Abstract

Warfarin, which is frequently used in the treatment of thromboembolism, is a potent anticoagulant. It is a narrow therapeutic index drug and there is a risk of bleeding when the therapeutic dose is exceeded. It interacts with many drugs and foods. Due to drug and food interactions, the effectiveness of treatment decreases or spontaneous bleeding occurs. Although drug interactions constitute a small part of adverse drug reactions, they are important because they cause predictable and preventable mortality and morbidity. Prevention of drug interactions provides shortened hospital stay, reduced readmission rate, and reduced treatment costs. Examining the treatment applied to patients in terms of drug interactions increases the effectiveness and reliability of the treatment. The purpose of this review is to increase the knowledge level of warfarin on drug and food interactions.

Keywords

Warfarin, drug interactions, food-drug interactions

References

• 1. Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. J Biol Chem. 1941; 138: 513-27.
• 2. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001927.
• 3. Hirsh J, Dalen J, Anderson D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001; 119(1 Suppl):8-21.
• 4. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med. 1994 Nov 1;121(9):676-83.
• 5. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002 Sep;36(9):1331-6.
• 6. Jonker DM, Visser SA, van der Graaf PH, et al. Towards a mechanism-based analysis of pharmacodynamic drug–drug interactions in vivo. Pharmacol Ther. 2005 Apr;106(1):1-18.
• 7. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003 Apr 2;289(13):1652-8.
• 8. Tanaka E. Clinically important pharmacokinetic drug–drug interactions: Role of cytochrome P450 enzymes. J Clin Pharm Ther. 1998 Dec;23(6):403-16.
• 9. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs. 1983 Jun;25(6):610-20.
• 10. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003 Aug;3(3):221-30.
• 11. Tadros R, Shakib S. Warfarin--indications, risks and drug interactions. Aust Fam Physician. 2010 Jul;39(7):476-9.
• 12. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ. 2002 Oct 12;325(7368):828-31.
• 13. Delaney JA, Opatrny L, Brophy JM, et al. Drug–drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007 Aug 14;177(4):347-51.
• 14. Marnett LJ, Rowlinson SW, Goodwin DC, et al. Arachidonic acid oxygenation by COX-1 and COX-2 mechanisms of catalysis and inhibition. J Biol Chem. 1999 Aug 13;274(33):22903-6.
• 15. Chan TY. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother. 1995 Dec;29(12):1274-83.
• 16. Musumba C, Pritchard DM, Pirmohamed M. Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. Aliment Pharmacol Ther. 2009 Sep 15;30(6):517-31.
• 17. Zhang Q, Bal-dit-Sollier C, Drouet L, et al. Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial. Eur J Clin Pharmacol. 2011 Mar;67(3):309-14.
• 18. Mahe I, Bertrand N, Drouet L, et al. Interaction between paracetamol and warfarin in patients: a double-blind, placebocontrolled, randomized study. Haematologica. 2006 Dec;91(12):1621-7.
• 19. Jones CB, Fugate SE. Levofloxacin and warfarin interaction. Ann Pharmacother. 2002 Oct;36(10):1554-7.
• 20. Carroll DN, Carroll DG. Interactions between warfarin and three commonly prescribed fluoroquinolones. Ann Pharmacother. 2008 May;42(5):680-5.
• 21. Baillargeon J, Holmes HM, Lin YL, et al. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med. 2012 Feb;125(2):183-9.
• 22. Mercadal Orfila G, Gracia García B, Leiva Badosa E, et al. Retrospective assessment of potential interaction between levofloxacin and warfarin. Pharm World Sci. 2009 Apr;31(2):224-9.
• 23. Schelleman H, Bilker WB, Brensinger CM, et al. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther. 2008 Nov;84(5):581-8.
• 24. Duncan D, Sayal K, McConnell H, et al. Antidepressant interactions with warfarin. Int Clin Psychopharmacol. 1998 Mar;13(2):87-94.
• 25. Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012 Oct 30;79(18):1862-5.
• 26. Teles JS, Fukuda EY, Feder D. Warfarin: pharmacological profile and drug interactions with antidepressants. Einstein (Sao Paulo). 2012 Jan-Mar;10(1):110-5.
• 27. Monastero R, Camarda R, Camarda C. Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease. Clin Ther. 2007 Dec;29(12):2706-9.
• 28. Rogers T, de Leon J, Atcher D. Possible interaction between warfarin and quetiapine. J Clin Psychopharmacol. 1999 Aug;19(4):382-3.
• 29. Yang FW, Liang CS. Multiple intracerebral hemorrhages in an elderly patient after adding quetiapine to a stable warfarin regimen. Gen Hosp Psychiatry. 2011 May-Jun;33(3):302.e1-2.
• 30. Zingone MM, Guirguis AB, Airee A, et al. Probable drug interaction between warfarin and hormonal contraceptives. Ann Pharmacother. 2009 Dec;43(12):2096-102.
• 31. Choi S, Oh DS, Jerng UM. A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin. PLoS One. 2017 Aug 10;12(8):e0182794.
• 32. Komperda KE. Potential interaction between pomegranate juice and warfarin. Pharmacotherapy. 2009 Aug;29(8):1002-6.
• 33. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol. 2005 Feb;45(2):127-32.
• 34. Norwood DA, Parke CK, Rappa LR. A Comprehensive Review of Potential Warfarin-Fruit Interactions. J Pharm Pract. 2015 Dec;28(6):561-71.
• 35. Stoysich AM, Lucas BD, Mohiuddin SM, et al. Further elucidation of pharmacokinetic interaction between diltiazem and warfarin. Int J Clin Pharmacol Ther. 1996 Feb;34(2):56-60.
• 36. Sutfin T, Balmer K, Boström H, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit. 1989;11(2):176-84.
• 37. Kates RE, Yee YG, Kirsten EB. Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther. 1987 Sep;42(3):305-11.
• 38. Bax ND, Lennard MS, Tucker GT, et al. The effect of betaadrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose. Br J Clin Pharmacol. 1984 May;17(5):553-7.
• 39. Scott AK, Park BK, Breckenridge AM. Interaction between warfarin and propranolol. Br J Clin Pharmacol. 1984 May;17(5):559-64.
• 40. Robinson DS, MacDonald MG. The effect of phenobarbital administration on the control of coagulation achieved during warfarin therapy in man. J Pharmacol Exp Ther 1966; 153: 250-3.
• 41. Thijssen HH, Flin ois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos. 2000 Nov;28(11):1284-90.
• 42. Marinella MA. Mesalamine and warfarin therapy resulting in decreased warfarin effect. Ann Pharmacother. 1998 Jul-Aug;32(7-8):841-2.
• 43. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother. 2003 Mar;37(3):367-70.
• 44. Glasheen JJ, Fugit RV, Prochazka AV. The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J Gen Intern Med. 2005 Jul;20(7):653-6.
• 45. Williams JR, Griffin JP, Parkins A. Effect of concomitantly administered drugs on the control of long term anticoagulant therapy. Q J Med. 1976 Jan;45(177):63-73.
• 46. Hedenmalm K, Lindh JD, Sawe J, et al. Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene. Eur J Clin Pharmacol. 2004 Jul;60(5):369-72.
• 47. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. Ann Pharmacother. 2004 Jan;38(1):50-2.
• 48. Monterrey-Rodríguez J. Interaction between warfarin and mango fruit. Ann Pharmacother. 2002 May;36(5):940-1.
• 49. Blickstein D, Shaklai M, Inbal A. Warfarin antagonism by avocado. Lancet. 1991 Apr 13;337(8746):914-5.
• 50. Cambria-Kiely JA. Effect of soy milk on warfarin efficacy. Ann Pharmacother. 2002 Dec;36(12):1893-6.